--- title: "Teva Reports Gap In Tardive Dyskinesia Diagnosis Among Patients With Mood Disorders" type: "News" locale: "en" url: "https://longbridge.com/en/news/286770746.md" description: "Teva Pharmaceuticals reported a significant gap in diagnosing tardive dyskinesia among patients with mood disorders, revealing that 85% of affected adults aged 18-29 experienced severe impacts, yet only 23% received a formal diagnosis. Patients waited over 3.5 years on average for diagnosis after symptoms appeared. These findings were shared at the American Psychiatric Association Annual Meeting." datetime: "2026-05-18T12:27:26.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286770746.md) - [en](https://longbridge.com/en/news/286770746.md) - [zh-HK](https://longbridge.com/zh-HK/news/286770746.md) --- # Teva Reports Gap In Tardive Dyskinesia Diagnosis Among Patients With Mood Disorders Add as your preferred news source on Google Add Now Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA) on Monday announced new real-world data from the IMPACT-TD Registry showing a significant gap in diagnosing tardive dyskinesia in patients with underlying mood disorders. The data showed that 85% of adults aged 18 to 29 with mood disorders living with tardive dyskinesia experienced moderate to severe impact from the condition, while only 23% had received a formal diagnosis. The analysis also found that patients waited an average of more than 3.5 years to receive a formal diagnosis after involuntary movements were first recognized. Tardive dyskinesia is a chronic movement disorder associated with certain mental health treatments and is characterized by uncontrollable and repetitive body movements. The findings were presented at the American Psychiatric Association Annual Meeting being held May 16-20 in San Francisco. For comments and feedback contact: editorial@rttnews.com Business News ### Related Stocks - [TEVA.US](https://longbridge.com/en/quote/TEVA.US.md) - [IHE.US](https://longbridge.com/en/quote/IHE.US.md) - [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [VHT.US](https://longbridge.com/en/quote/VHT.US.md) - [XLV.US](https://longbridge.com/en/quote/XLV.US.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) ## Related News & Research - [14:05 ETLupin Receives Tentative Approval from U.S. FDA for Revefenacin Inhalation Solution](https://longbridge.com/en/news/286805922.md) - [Shah Capital Management Will Vote ‘No' Across Five Proposals On Novavax's June 18 Ballot - SEC Filing](https://longbridge.com/en/news/286565204.md) - [AbbVie Inc. $ABBV Shares Purchased by RiverFront Investment Group LLC](https://longbridge.com/en/news/286750290.md) - [Eton Pharmaceuticals Adds Another 2026 Launch As It Secures U.S. Rights To IMPAVIDO](https://longbridge.com/en/news/287025596.md) - [](https://longbridge.com/en/news/286807703.md)